Pfizer, Inc. vs Genentech, Inc.

Order Granting Patent Owner's Renewed Motion to Seal

Renewed Motion to Seal

Ex 2005 Genentech Notebook 10840 John Brady PUBLIC

Ex 2001 Genentech Notebook 10098 Leonard Presta PUBLIC

Ex 2002 Genentech Notebook 10823 Leonard Presta PUBLIC

Ex 2006 Genentech Notebook 11162 John Brady PUBLIC

Final Written Decision

Petitioner Pfizer's Updated Mandatory Notices

Patent Owner's Updated Mandatory Notice

Hearing Transcript

Patent Owner's Objections to Demonstratives

Petitioners Objections to Patent Owners Demonstrative Exhibits

Granting Petitioner's Unopposed Motion for Pro Hac Vice Admission of Sharick Naqi 37 C.F.R. sec. 42.10

Petitioners Updated Exhibit List

Patent Owner's Updated Exhibit List

Transcript of Conference Call dated June 19, 2018

Petitioner¿¿¿s Motion for Pro Hac Vice Admission of Sharick Naqi

Declaration of Sharick Naqi in Support of Petitioner¿¿¿s Motion for the Pro Hac Vice Admission

Petitioner Pfizers Updated Mandatory Notices

Amending Grant of Request for Oral Argument

Exhibit 3003

Patent Owner's Reply ISO Motion to Exclude

Petitioners Reply in Support of Their Motion to Exclude Evidence

Petitioners Opposition to Patent Owners Motion to Strike Pursuant to Paper No. 60

Petitioners Opposition to Patent Owners Motion to Exclude Evidence

Petitioners' Responses to Patent Owner¿¿¿s Observations on Cross-Examination of Jefferson Foote, Ph.D

Patent Owner's Opposition to Petitioners' Motion to Exclude

Ex 3002

Granting Request for Oral Argument 37 C.F.R. § 42.70

Patent Owner's Motion to Strike

Patent Owner's Motion to Exclude Evidence

Foote Deposition Transcript

Patent Owner's Request for Oral Argument

Patent Owner's Motion for Observations on Cross-Exam of Foote

Petitioners Request for Oral Argument

Petitioners Motion to Seal

Petitioners Motion to Exclude Evidence [SEALED]

Petitioners Motion to Exclude Evidence [PUBLIC]

Authorizing Briefing on Motion to Strike 37 C.F.R. § 42.5

Patent Owner's Notice of Deposition of Foote

Patent Owner's Objection to Evidence

Petitioners Motion to Seal

Petitioners Evidentiary Objections

Petitioners Reply to Patent Owners Response (PUBLIC)

Presta, Humanized Monoclonal Antibodies, 29 Ann. Rep. in Med. Chemistry 317-24 (1994)

Deposition Transcript of Paul J. Carter, dated April 27, 2018

Deposition Transcript of Irene Loeffler, dated May 1, 2018

Deposition Transcript of John B. Ridgway Brady, dated April 27, 2018

Reply Declaration of Jefferson Foote

Reply Declaration of Christopher Lowden

Reply Declaration of Benjamin Lasky

Petitioners Reply to Patent Owners Response (Sealed)

Foote, Humanized Antibodies [Foote Dep Ex]

Kolbinger, et al., Humunization of a Mouse Anti-Human IgE Antibody: A Potential Therapeutic for IgE-Mediated Allergies, 6(8) PROTEIN ENGINEERING 971¿¿¿980 (1993)

DAVID J. KING, APPLICATIONS AND ENGINEERING OF MONOCLONAL ANTIBODIES (1998)

Deposition Transcript of Ian A. Wilson, dated April 21, 2018

Deposition Transcript of Paul J. Carter, dated April 27, 2018

Deposition Transcript of Leonard G. Presta, dated May 1, 2018

Deposition Transcript of Leonard G. Presta, dated May 1, 2018

Deposition Transcript of Irene Loeffler, dated May 1, 2018

Deposition Transcript of John B. Ridgway Brady, dated April 27, 2018

Reply Declaration of Jefferson Foote

Foote & Winter, Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops, 224 J.MOLECULAR BIOLOGY 487-499 (1991).

Hale et al., Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody Campath-1H, 332 LANCET 1394-1399 (1988).

Mathieson et al., Monoclonal Antibody Therapy in Systemic Vasculitis, 323(4) NEW ENG. J.MED. 250-254 (1990).

Kyle et al., Humanized Monoclonal Antibody Treatment in Rheumatoid Arthritis, 18(11) J. RHEUMATOLOGY 1737-1738 (1991).

Brown, Jr. et al., Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor Prolongs Primate Cardiac Allograft Survival, 88 PROC. NAT¿¿¿L. ACAD. SCI. U.S. 2663-2667 (1991).

Havrdova, et. al., Alemtuzumab in the Treatment of Multiple Sclerosis: Key Clinical Trial Results and Considerations for Use, 8(1) THERAPEUTIC ADVANCES IN NEUROLOGICAL. DISORDERS 31-45 (2015).

Library of Congress Copyright Record for Presta ¿¿¿94

Joint Notice of Stipulation to Revise Schedule

Petitioner Pfizer¿¿¿s Notice of Deposition of Dr. Leonard G. Presta

Petitioner Pfizers Notice of Deposition of Irene Loeffler

Notice of Deposition of John R. Brady

Notice of Deposition of Dr. Paul J. Carter

Petitioner Pfizers Notice of Deposition of Dr. Ian A. Wilson Under C.F.R. 42.53

Patent Owner's Updated Mandatory Notice

Petitioner Pfizers Objections To Admissibility Of Evidence

Wilson Expert Declaration

Trail Transcript - Sinomab Bio. v. Immunomedics

Brekke - Nature Reviews 2003

Waldmann - Science 1991

About HNCs and HNDs

Motion to Seal

Foote Deposition Transcript

Buss Deposition Transcript

US Patent No. 7375193

US Patent No. 7560111

Presta - J. Immunology 1993

Bondi - J. Physical Chemistry 1964

Man Sung Co - J. Immunology 1992

Winter - TiPS 1993

Ball Declaration IPR2016-01694

Redline of Ball / Buss Declarations IPR2016-01694

Patent Owner's Response PARTIES BOARD ONLY

Patent Owner's Response

Decision (IPR2017-02139) - Institution of Inter Partes Review and Grant of Motion for Joinder

Patent Owner's Second Updated Mandatory Notices

Petitioner Pfizers Updated Mandatory Notices

ORDER Revising Due Date 7

Patent Owner's Notice of Deposition of Timothy Buss

Patent Owner's Notice of Deposition of Jefferson Foote

Joint Notice of Stipulation of Due Date 1 and 2

Decision - Institution of Inter Partes Review (republished as non-confidential)

Erratum (republished as non-confidential)

Erratum

Joint Statement re the Institution Decision

PO Objection to Evidence

Petitioner's Objections to Admissibility of Evidence

Petitioner's Updated Mandatory Notices

Decision Institution of Inter Partes Review

Case Management and Scheduling Order

Patent Owner's Updated Mandatory Notices

Decision - Granting Petitioner's Unopposed Motions for Pro Hac Vice Admission of Sarah K. Tsou, Benjamin A. Lasky, Mark C. McLennan, and Christopher J. Citro

Decision - Grant of Patent Owners Motion to Seal and Entry of Stipulated Protective Order

Petitioners Updated Power of Attorney

Petitioners Motion for the Pro Hac Vice Admission of Christopher J. Citro

Petitioners Updated Mandatory Notices

Petitioners Motion for the Pro Hac Vice Admission of Sarah K. Tsou

Declaration of Sarah K. Tsou in Support of Petitioners Motion for the Pro Hac Vice Admission

Petitioners Motion for the Pro Hac Vice Admission of Benjamin A. Lasky

Declaration of Benjamin A. Lasky in Support of Petitioners Motion for the Pro Hac Vice Admission

Petitioners Motion for the Pro Hac Vice Admission of Mark. C. McLennan

Declaration of Mark. C. McLennan in Support of Petitioners Motion for the Pro Hac Vice Admission

Declaration of Christopher J. Citro in Support of Petitioners Motion for the Pro Hac Vice Admission

Petitioners First Amended Appendix of Exhibits

Petitioner¿¿¿s Updated Mandatory Notices

Order - re Petitioner's Request for Authorization to Correct IPR2017-01489 Petition and to File Reply Briefs

E-mail from Petitioner, Sept. 21, 2017

Decision Granting Patent Owner's Unopposed Motions for Pro Hac Vice Admission of Daralyn J. Durie, Robert J. Gunther, Lisa J. Pirozzolo, Kevin S. Prussia, and Andrew J. Danford

Patent Owner's Unopposed Motion for Admission Pro Hac Vice of Daralyn J. Durie

Declaration of Robert J. Gunther, Jr. in Support of Motion for Admission Pro Hac Vice

Patent Owner's Unopposed Motion for Admission Pro Hac Vice of Robert J. Gunther, Jr.

Declaration of Daralyn J. Durie in Support of Patent Owner's Motion for Pro Hac Vice Admission

Patent Owner's Unopposed Motion for Admission Pro Hac Vice of Lisa J. Pirozzolo

Patent Owner's Unopposed Motion for Admission Pro Hac Vice of Kevin S. Prussia

Declaration of Kevin S. Prussia in Support of Motion for Admission Pro Hac Vice

Patent Owner's Unopposed Motion for Admission Pro Hac Vice of Andrew J. Danford

Declaration of Andrew J. Danford in Support of Motion for Admission Pro Hac Vice

Declaration of Lisa J. Pirozzolo in Support of Motion for Admission Pro Hac Vice

Ex 2011 Genentech Interoffice Memo from Carter to Presta_PARTIES BOARD ONLY

Patent Owner's Preliminary Response_PARTIES BOARD ONLY

Ex 2001Genentech Notebook 10098 Leonard Presta _PARTIES BOARD ONLY

Ex 2002 Genentech Notebook 10823 Leonard Presta _PARTIES BOARD ONLY

Ex 2003 Genentech Notebook 11268 Paul Carter_PARTIES BOARD ONLY

Ex 2004 Genentech Notebook 11643 Paul Carter_PARTIES BOARD ONLY

Ex 2005 Genentech Notebook 10840 John Brady_PARTIES BOARD ONLY

Ex 2006 Genentech Notebook 11162 John Brady_PARTIES BOARD ONLY

Ex 2007 Excerpts from Genentech Notebook 11008 Ann Rowland_PARTIES BOARD ONLY

Ex 2008 Excerpts from Genentech Notebook 11297 Tim Hotaling_PARTIES BOARD ONLY

Ex 2009 Excerpts from Genentech Notebook 11568 Monique Carver_PARTIES BOARD ONLY

Ex 2010 Genentech Interoffice Memo from Carter to Presta and Henner_PARTIES BOARD ONLY

Ex 2012 Genentech Synthetic DNA Requests_PARTIES BOARD ONLY

Ex 2013 Genentech Synthetic DNA Requests PARTIES BOARD ONLY

Ex 2014 Genentech Protein Engineering of 4D5 Status Report_PARTIES BOARD ONLY

Ex 2015 Genentech Interoffice Memo re RCC Minutes and Recommendations_PARTIES BOARD ONLY

Ex 2016 Presta Declaration 1488_PARTIES BOARD ONLY

Ex 2017 Carter Declaration Pfizer 1488_PARTIES BOARD ONLY

Ex 2018 Brady Decl 1488_PARTIES BOARD ONLY

Ex 2019 Loeffler Declaration Pfizer 1488

Ex 2020 Carter 1992

Ex 2021 Presta 1997

Ex 2022 Bruggerman 1989

Ex 2023 Kalsi 1999

Ex 2024 Gorman 1991

Ex 2025 Isaacs 1992

Ex 2026 Kabat 1987

Ex 2027 Tramontano 1990

Ex 2028 Shepard 2008

Ex 2029 Excerpt from Roche Finance Report 2016

Ex 2030__Modified Default Standing Protective Order and Certification 1488

EX 2031 Modified Default Standing Protective Order 1488_Redline

Ex 2032 File History for US Patent Application No 07_715272

Ex 2033 Shearman

Ex 2016 Presta Declaration PUBLIC

Ex 2017 Carter Declaration Pfizer_PUBIC

Ex 2018 Brady Decl_PUBLIC

Patent Owner's Preliminary Response

Patent Owner's Motion to Seal

Patent Owner's Mandatory Notices

Genentech Power of Attorney

Notice of Accord Filing Date

File History for U.S. Patent No. 6,407,213 Vol.01

File History for U.S. Patent No. 6,407,213 Vol.02

PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 6,407,213 UNDER 35 U.S.C. 311 AND 37 C.F.R. 42.100

PFIZER, INC. POWER OF ATTORNEY

U.S. Patent No. 6,407,213

File History for U.S. Patent No. 6,407,213 Vol.03

File History for U.S. Patent No. 6,407,213 Vol. 4

File History for U.S. Patent No. 6,407,213 Vol. 5

File History for U.S. Patent No. 6,407,213 Vol. 6

File History for U.S. Patent No. 6,407,213 Vol. 7

File History for U.S. Patent No. 6,407,213 Vol. 10

Hudziak p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

Prabakaran, The Quest for a Magic Bullet

Sears et al., Phase-I Clinical Trial of Monoclonal Antibody in Treatment of Gastrointestinal Tumours,

Protein Data Bank - Chronology

File History for U.S. Patent No. 6,407,213 Vol. 8

File History for U.S. Patent No. 6,407,213 Vol. 9

Declaration of Dr. Foote in Support of Petition for Inter Partes Review of Patent No. 6,407,213

Declaration of Mr. Buss in Support of Petition for Inter Partes Review of Patent No. 6,407,213

Kohler Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity

Marks, The Story of Cesar Milstein and Monoclonal Antibodies: A Healthcare Revolution in the Making

Cosimi Treatment of Acute Renal Allograft Rejection with OKT3 Monoclonal Antibody,

Ortho Multicenter Transplant Study Group, A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadveric Renal Transplants

Jaffers et al., Monoclonal Antibody Therapy: Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression

Sikora, Monoclonal Antibodies in Oncology,

Morrison et al., Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains,

Jones et al., Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse

Kirkman et al., Early Experience with Anti-Tac in Clinical Renal Transplantation,

Vincenti et al., Interleukin 2 Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation

Harris et al., Medical Progress: Breast Cancer

Semba et al., A v-erbB-Related Protooncogene, c-erbB-2, is Distinct from the c-erbB-1 / Epidermal Growth Factor-Receptor Gene and is Amplified in a Human Salivary Gland Adenocarcinoma

Coussens et al., Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene,

Hudziak et al., Increased Expression of the Putative Growth Factor Receptor p185HER2 Causes Transformation and Tumorigenesis of NIH 3T3 Cells.

Shepard et al., Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic,

Queen, International Publication No. WO 1990/07861

Liu et al., Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis of Cancer Cells

Queen et al., A Humanized Antibody That Binds to the Interleukin 2 Receptor

Waldmann et al., The Interleukin-2 Receptor: A Target for Monoclonal Antibody Treatment of Human T-Cell Lymphotrophic Virus I-Induced Adult T-Cell Leukemia

Hakimi et al., Reduced Immunogenicity and Improved Pharmacokinetics of Humanized ANTI-Tac in Cynomolgus Monkeys

SEER Stat Fact Sheets: Breast Cancer, National Cancer Institute,

King et al., Amplification of a Novel v-erbB Related Gene in a Human Mammary Carcinoma,

Fukushige et al., Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and its Amplification in a Gastric Cancer Cell Line

Slamon et al., Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene,

Kraus et al., Overexpression of the EGF Receptor-Related Proto-Oncogene erbB-2 in Human Mammary Tumor Cell Lines by Different Molecular Mechanisms,

Chothia et al., Conformations of Immunoglobulin Hypervariable Regions,

Kabat et al., Sequences of Proteins of Immunological Interest: Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for Antigen, T-Cell Surface Antigens, b2-Microglubin

Kabat et al., Sequences of Proteins of Immunological Interest: Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptor for Antigen, T-Cell Surface Antigens

Amit et al., Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8

Riechmann et al., Reshaping Human Antibodies for Therapy

Tramontano et al., Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the VH Domains of Immunoglobulins

Davies & Metzger, Structural Basics of Antibody Function

Chothia & Lesk, Canonical Structures for the Hypervariable Regions of Immunoglobulins,

Chothia et al., Domain Association in Immunoglobulin Molecules: The Packing of Variable Domain

Verhoeyen et al., Reshaping Human Antibodies: Grafting an Antilysozyme Activity,

Kurrle et al., EP Publication Number 0403156, Improved Monoclonal Antibodies Against the Human Alphabeta T-Cell Receptor, Their Production and Use

Kabat et al., Sequences of Proteins of Immunological Interest: Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursor

Saul et al., Preliminary Refinement and Structural Analysis of the Fab Fragment from Human Immunoglobulin New at 2.0 Resolution

Winter et al., EP Publication Number 0239400, Recombinant Antibodies and Methods for Their Productions

Bernstein et al., The Protein Data Bank: A Computer-based Archival File for Macromolecular Structures

Sheriff et al., Three-Dimensional Structure of an Antibody- Antigen Complex

Marquart et al., The Three-Dimensional Structure of Antibodie

Satow et al., Phosphocholine Binding Immunogloubulin Fab McPC306 An X-ray Diffraction Study

Herron et al., Three-Dimensional Structure of a Fluorescein-Fab Complex Crystallized in 2-Methyl-2,4-Pentanedio

Padlan et al., Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL-10 Fab-Lysozyme Complex,

Kumar et al., Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells,

Soomro et al., C-erbB-2 Expression in Different Histological Types of Invasive Breast Carcinoma

Edelman et al., The Covalent Structure of an Entire gG Immunoglobulin Molecule

Capra & Kehoe, Variable Region Sequences of Five Human Immunoglobulin Heavy Chains of the VHIII Subgroup: Definitive Identification of Four Heavy Chain Hypervariable Regions,

Morin, From Oncogene to Drug: Development of Small Molecule Tyrosine Kinase Inhibitors as Anti-Tumor and Anti-Angiogenic Agents,

Patent Interference No. 105,744 Vol. 1

Patent Interference No. 105,744 Vol. 2

Patent Interference No. 105,744 Vol. 4

Wilson & Goulding, A Biologists Guide to Principles and Techniques of Practical Biochemistry

Patent Interference No. 105,744 Vol. 3

Patent Interference No. 105,744 Vol. 5

Patent Interference No. 105,744 Vol. 6

Patent Interference No. 105,744 Vol. 8

Patent Interference No. 105,744 Vol. 12

Patent Interference No. 105,744 Vol. 13

Patent Interference No. 105,744 Vol. 7

Patent Interference No. 105,744 Vol. 9

Patent Interference No. 105,744 Vol. 11

Patent Interference No. 105,744 Vol. 10

Patent Interference No. 105,744 Vol. 14

Patent Interference No. 105,744 Vol. 15

U.S. Patent No. 5,677,171, Monoclonal Antibodies Directed to the HER2 Receptor

Sambrook et al., Molecular Cloning: A Laboratory Manual

Colman et al., Three-Dimensional Structure of a Complex of Antibody with Influenza Virus Neuraminidase

Bender et al., Immunogenicity, Efficacy and Adverse Events of Adalimumab in RA Patients

Koprowski et al., Human Anti-Idiotype Antibodies in Cancer Patients: Is the Modulation of the Immune Response Beneficial for the Patient

Brient & Nisonoff, Quantitative Investigations of Idiotypic Antibodies. IV. Inhibition by Specific Haptens of the Reaction of Anti-Hapten Antibody with Its Anti-Idiotypic Antibody

Chanh et al., Monoclonal Anti-Idiotypic Antibody Mimics the CD4 Receptor and Binds Human Immunodeficiency Virus

Schroff et al., Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therap

Suh et al., The Galactan-Binding Immunoglobulin Fab J539

Furey et al., Structure of A Novel Bence-Jones Protein (Rhe) Fragment at 1.6¿¿ Resolution

Co et al., Humanized Antibodies for Antiviral Therapy

Wallick et al., Glycosylation of A VH Residue of a Monoclonal Antibody Against a(L-6) Dextran Increases its Affinity for Antigen

Library of Congress Copyright Record for Jaffers 86

Library of Congress Copyright Record for Morrison 84

Library of Congress Copyright Record for Jones 86

Library of Congress Copyright Record for Kirkman 89

Library of Congress Copyright Record for Hakimi 91

Library of Congress Copyright Record for Harris 92

Library of Congress Copyright Record for Semba 85

Library of Congress Copyright Record for Hudziak 87

Library of Congress Copyright Record for Davies & Metzger

Library of Congress Copyright Record for Amit 86

Abdou et al., Network Theory in Autoimmunity. In Vitro Suppression of Serum Anti-DNA by Anti-idiotypic Antibody in Systemic Lupus Erythematosus

Epp et al., The Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-Jones Protein REI Refined at 2.0 Resolution

Mian, Structure, Function and Properties of Antibody Binding Sites

Poljak et al., The Three-Dimensional Structure of the Fab Fragment of A Human Myeloma Immunoglobulin at 2.0-Resolution,

Padlan et al., Model Building Studies of Antigen-binding Sites: the Hapten Binding Site of MOPC-315

Segal et al., The Three-Dimensional Structure of a Phosphorylcholine-Binding Mouse Immunoglobulin Fab and the Nature of the Antigen Binding Site

Jones, Diffraction Methods for Biological Macromolecules. Interactive Computer Graphics: FRODO, 115 Methods Enzymology

Excel Trick, History of Microsoft Excel 1978-2013

U.S. Patent No. 4,891,762

Library of Congress Copyright Record for Cosimi 81

Library of Congress Copyright Record for OMTSG 85

Library of Congress Copyright Record for Liu 87

Library of Congress Copyright Record for Queen 89

Library of Congress Copyright Record for Waldamnn 93

Library of Congress Copyright Record for Vincenti 98

Library of Congress Copyright Record for King 85

Library of Congress Copyright Record for Coussens 85

Library of Congress Copyright Record for Slamon 87

Library of Congress Copyright Record for Chothia 89

Library of Congress Copyright Record for Verhoeyen 88

Library of Congress Copyright Record for Riechmann 88

Library of Congress Copyright Record for Saul 78

Library of Congress Copyright Record for Padlan 89

Library of Congress Copyright Record for Colman 87

Library of Congress Copyright Record for Koprowski 84

Library of Congress Copyright Record for Chanh 87

Library of Congress Copyright Record for Schroff 85

Library of Congress Copyright Record for Jones 85

Library of Congress Copyright Record for Co 91

Bodmer, International Publication No. WO 1989/01783 (published March 9, 1989)

Declaration of Karen Younkins

Library of Congress Copyright Record for Miller 98

Library of Congress Copyright Record for Sheriff 87

Library of Congress Copyright Record for Suh 86

Library of Congress Copyright Record for Wallick 88

Gorman, International Publication No. WO 1992/05274 (published April 2, 1992)

Miller, To Build a Better Mousetrap, Use Human Parts

Declaration of Amanda Hollis

Declaration of Christopher Lowden